Santarus Zegerid: better NAB control than Nexium/Prevacid
San Diego, USA-based Santarus, a drugmaker focused on gastrointestinal disorders, presented strong clinical data on its proton pump inhibitor, Zegerid (omeprazole/sodium bicarbonate), at the Digestive Disease Week 2006 meeting.
The clinical study evaluated night-time gastric acidity in patients with nocturnal symptoms of gastroesophageal reflux disease who were treated with 40mg Zegerid powder for oral suspension, Nexium (esomeprazole magnesium) delayed-release capsules 40mg and Prevacid (lansoprazole) delayed-release capsules 30mg on an empty stomach at bedtime.
According to the firm, the results indicate that Zegerid allows fewer episodes of nocturnal acid breakthrough (NAB) than the comparator drugs, and that dosing the agent at bedtime on an empty stomach provided more rapid control of gastric acid in the first half of the night, a critical period for control.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze